GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: satiety stopped being a problem at week 25 — 26 comments in the full submission. View in context.
694
c/cagrilintide·submitted 1 year ago by u/ferran_mensah

small win: satiety stopped being a problem at week 25

Trial Databranch of 6 comments

Something I noticed reading old threads that I have not seen said out loud. The advice on REDEFINE in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers with…

Read the full submission and all 26 comments →

This branch

6 comments, started 1 year ago
u/nl_verzekering116 points·1 year ago
no
replysharereportpermalink
u/ferran_mensahOP82 points·1 year ago

CagriSema ratios in trials are fixed, do not extrapolate self-mixing

replysharereportpermalink
[deleted]34 points·1 year ago

[deleted]

replysharereportpermalink
u/ferran_mensahOP59 points·1 year ago

The satiety on amylin analogs is described as physically different. GLP-1 reduces appetite noise, amylin does co-agonism.

replysharereportpermalink
u/ferran_mensahOP42 points·1 year ago

The satiety on amylin analogs is described as physically different.

Disagree on that part. 98.1% and 99.3% on the same vial is normal.

replysharereportpermalink
u/karim_restrepo33 points·1 year ago

amylin receptor distribution is different from GLP-1

replysharereportpermalink

← back to the whole thread

About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/cagrilintide
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/amylin_amyu/incretin_ivyu/ledger_mod
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →